Biopharmaceutical company Citius Oncology announced that it has signed an exclusive distribution agreement with Europe's leading healthcare product provider Uniphar, officially expanding the commercialization of its innovative lymphoma therapy Lymphir™ to the EU market.

This collaboration will leverage Uniphar's established distribution network in Europe to accelerate the market access process of Lymphir™ in the EU region. The agreement not only strengthens Citius Oncology's global strategic layout, but also provides European patients with more advanced treatment options. As a targeted therapy for specific lymphoma subtypes, Lymphir™ has previously demonstrated clinical potential in certain international markets. Through this channel expansion, Citius Oncology is expected to further enhance its international influence in the field of oncology treatment.